Roche Bids for Rest of Genentech
Updated from 8:08 a.m. EDT
Swiss drug company Roche made an offer to take over the stake it doesn't already own in biotech behemoth Genentech (DNA) for $89 a share, or $43.7 billion.
Many observers on Wall Street will likely expect Genentech investors to view the bid as low, but they also probably see it has a preliminary approach. As evidence, shares of South San Francisco, Calif.-based Genentech, which closed at $81.82 on Friday, were surging past the Roche price in premarket trading Monday, rising 18% to $96.60.
Roche owns roughly 55.9% of the largest biotech by market cap. The proposal for the remaining 44.1% is an 8.8% premium to the company's closing price on the last trading day of the prior week and a 19% premium to the price a month ago.Shares of Genentech have traded between $65.35 and $82.50 in the past year. For Roche's part, the acquisition is expected to generate pretax cost savings of roughly $750 million to $850 million annually and add to earnings per share in the first year after the deal closes. "In our view, the financial/operational synergies are clear," wrote JPMorgan analyst Geoffrey Meacham in a research note to investors. "That said, we believe the offer substantially undervalues Genentech's pipeline, particularly the Avastin opportunity for adjuvant colon as well as breast, prostate and
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV